Loading…
TWST
Twist Bioscience Corp
NASDAQ· Healthcare· Biotechnology· CUSIP 90184D100
$135.47-9.16%Price as of Oct 23, 00:47 UTC · updated once a day, after the close
At a glance
Twist Bioscience Corp (TWST) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in South San Francisco, United States and has 979 employees. The company is worth $8.98B. Revenue was $376.57M in fiscal 2025, up 20.3% from the year before. It reported a net loss of $77.67M. The share price is 38.3% below its 52-week high of $219.71. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Baillie Gifford (Baillie Gifford & Co), at $111.81M. In that quarter, 2 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $21.36M of its stock on the open market and bought none. $1.97M of those sales were scheduled in advance under 10b5-1 plans.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $8.98B
- P/E
- —
- Forward P/E
- —
- P/B
- 19.0x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$2.23
- ROE
- -29.59%
- Profit margin
- -31.66%
- Revenue growth
- +23.20%
- Beta
- 2.19
- 52-week high
- $219.71
- 52-week low
- $23.30
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Baillie GiffordReducedBaillie Gifford & Co · Q2 2026$111.81M1.09M shares · 0.1% of portfolio
Ken GriffinReducedCitadel Advisors · Q2 2026$88.69M862.04K shares · 0.1% of portfolio- Israel EnglanderHeldMillennium Management · Q2 2026$35.71M347.15K shares · 0.0% of portfolio
- Cliff AsnessHeldAQR Capital Management · Q2 2026$13.31M129.39K shares · 0.0% of portfolio
- Two SigmaAddedTwo Sigma Investments · Q2 2026$9.73M94.6K shares · 0.0% of portfolio
Ray DalioNew positionBridgewater Associates · Q2 2026$1.92M18.65K shares · 0.0% of portfolio
Price over time
▲ +39.0% over 5Y.
today you would have $1,117.42▲ +11.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 8 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $31.72 | $46.47 | $36.86 | $23.81 | $77.39 | $141.29 | $21.00 | $23.09 | |
| P/S | 8.7x | 5.2x | 8.8x | 8.7x | 6.6x | 29.0x | 70.8x | 12.8x | 2.9x |
| P/B | 4.6x | 4.1x | 5.8x | 3.4x | 1.7x | 6.6x | 19.0x | 4.6x | — |
| EPS | -$1.30 | -$3.60 | -$3.60 | -$4.04 | -$3.15 | -$3.57 | -$3.92 | -$25.51 | |
| Profit margin | -110.98% | -20.63% | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% |
| ROE | -32.82% | -16.42% | -44.16% | -32.82% | -27.60% | -26.19% | -41.61% | -70.80% | — |
Median of the years shown; P/E years above 200x are left out.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CAICaris Life Sciences, Inc. | $31.71 | 19.1x | 15.1x | 0.00% | 20.13% | $8.96B |
| PTGXProtagonist Therapeutics, Inc | $139.53 | 134.2x | 10.7x | 0.00% | 10.98% | $9.03B |
| TXG10x Genomics, Inc. | $69.75 | — | 11.0x | 0.00% | -9.40% | $9.09B |
| HNGEHinge Health, Inc. | $109.93 | 36.3x | 25.6x | 0.00% | 30.38% | $8.87B |
| KYMRKymera Therapeutics, Inc. | $110.85 | — | 6.1x | 0.00% | -24.15% | $9.12B |
| IBRXImmunityBio, Inc. | $8.31 | — | — | 0.00% | — | $8.81B |
About the company
- 979
- South San Francisco, United States